Table 2.
Comparison of the ability of oGRP(1-46) and other activators of human bombesin receptors to stimulate phospholipase C activity in different human small cell lung cancer cell lines (SCLC).
| Experimental/control | |||||
|---|---|---|---|---|---|
| SCLC CELL | NMB | [D-Phe6, β-Ala11, Phe13, Nle14] Bn(6-14) | GRP | oGRP(1-46) | oGRP(1-46) + GRPR or NMBR antagonist |
| (0.1 uM) | (0.1 uM) | (0.1 uM) | (0.1 uM) | (0.1 uM) | |
| NCI-H69 | 1.03±0.06 | 1.31±0.04** | 1.23±0.07* | 1.10±0.02** | 0.99±0.06 |
| NCI-N417 | 1.01±0.06 | 3.14±0.34** | 1.03±0.01 | 0.99±0.05 | 0.96±0.08 |
| NCI-H209 | 1.25±0.11* | 1.17±0.03** | 1.11±0.04 | 1.17±0.04** | 1.01±0.06 |
| NCI-N592 | 1.08±0.06 | 1.05±0.04 | 1.03±0.04 | 1.01±0.04 | 1.05±0.02 |
The ability to activate phospholipase C and stimulate [3H]IP breakdown was determined for each of the Bn related peptides and oGRP(1-46), either alone or in the presence of a GRPR receptor antagonist ([(3-Ph-Pr6), His7, D-Ala11, D-Pro13, ψ (13–14), Phe14]Bn(6-14)NH2 [1 uM]) or a NMBR receptor antagonist (PD 168368)[1 uM]. Results are expressed as the experimental value divided by the control value. Results are means±SEM and are the average of at least 4 experiments.
p<0.05,
p<0.01 compared to no additions. Abbreviations (Jensen etal. 2008); SCLC, small cell lung cancer cells; β-Ala, β-alanine; Nle, norleucine; others -see Table 1 footnote.